期刊
ANTIVIRAL RESEARCH
卷 89, 期 1, 页码 26-34出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2010.11.002
关键词
alpha-Glucosidase; Imino sugar; Dengue virus; Ribavirin; Combination
资金
- NIH [AI061441, AI084267-0109]
- Hepatitis B Foundation through Commonwealth of Pennsylvania
- Glycobiology Institute
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061441, R43AI084267] Funding Source: NIH RePORTER
Cellular alpha-glucosidases I and II are enzymes that sequentially trim the three terminal glucoses in the N-linked oligosaccharides of viral envelope glycoproteins. This process is essential for the proper folding of viral glycoproteins and subsequent assembly of many enveloped viruses, including dengue virus (DENV). Imino sugars are substrate mimics of alpha-glucosidases land II. In this report, we show that two oxygenated alkyl imino sugar derivatives. CM-9-78 and CM-10-18, are potent inhibitors of both alpha-glucosidases land II in vitro and in treated animals, and efficiently inhibit DENV infection of cultured human cells. Pharmacokinetic studies reveal that both compounds are well tolerated at doses up to 100 mg/kg in rats and have favorable pharmacokinetic properties and bioavailability in mice. Moreover, we showed that oral administration of either CM-9-78 or CM-10-18 reduces the peak viremia of DENV in mice. Interestingly, while treatment of DENV infected mice with ribavirin alone did not reduce the viremia, combination therapy of ribavirin with sub-effective dose of CM-10-18 demonstrated a significantly enhanced antiviral activity, as indicated by a profound reduction of the viremia. Our findings thus suggest that combination therapy of two broad-spectrum antiviral agents may provide a practically useful approach for the treatment of DENV infection. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据